Externally Sponsored Research
Gilead Sciences funds investigator-initiated and collaborative research to advance clinical knowledge in virology, oncology, and inflammation through its Externally Sponsored Research program.
Funder: Gilead Sciences
Due Dates: January 30, 2026 (HIV Prevention - INCLUSION Global 2026 LOI) | May 4, 2026 (HIV: RESONATE 2026, BIC/LEN LOI) | June 30, 2026 (AmBisome RFP Topic of Interest LOI)
Funding Amounts: No fixed maximum; support may include direct funding and/or study drug; award size and duration vary by project and RFP.
Summary: Supports investigator-initiated and collaborative research on Gilead products or therapeutic areas to advance clinical knowledge and patient care.
Description
Gilead Sciences' Externally Sponsored Research program funds high-quality, impactful research conducted by independent investigators, academic centers, community organizations, and other external entities. The program is designed to generate evidence that informs clinical decision-making and improves patient outcomes in Gilead’s key therapeutic areas, including virology (HIV, hepatitis, emerging viruses, fungal diseases), oncology, and inflammation. Both Investigator Initiated Research (IIR) and Collaborative Research are supported, with the latter involving closer partnership with Gilead in aspects such as study design or data analysis. Support may include funding, study drug provision, or both, and research may target unmet needs, implementation science, or innovative clinical and epidemiological questions.
